Xbrane And Stada Celebrate Major Milestone With EU Filing For Lucentis Rival

Xlucane Asset Joins Bioeq/Formycon FYB201 Biosimilar With EMA

 
• By Dean Rudge
  
Europe_Map_Connection
Xbrane reported top-line Phase III data in June • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products